Our results demonstrate that not all tumour-infiltrating T cells are specific for tumour antigens... measuring CD39 expression could be a straightforward way to quantify or isolate bystander T cells. Read MoreDownload Attachment
Life Sciences Drug DevelopmentCambridge, MA
immunoSCAPE enables immunotherapy through high dimensional immune profiling solutions specializing in antigen specific T cell discovery and characterization.
immunoSCAPE meets needs for biomarker identification, assessment of treatment efficacy, identification of vaccine correlates and the discovery of novel therapeutic targets.
immunoSCAPE enables lower candidate attrition rate, mitigation of clinical trial failure risk and the understanding of trial failures, and the replenishment of pipelines with new targets and drug candidates.